Human LDL receptor enhances sequestration of apoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 6, 2008, Pages 1104-1110

  Altenburg, Michael ^a   Arbones Mainar, Jose ^a   Johnson, Lance ^a   Wilder, Jennifer ^a   Maeda, Nobuyo ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Lipoprotein metabolism; Mouse models; Recombinant adenovirus; Space of Disse

Indexed keywords

APOLIPOPROTEIN E4; FLUORESCENT DYE; HYBRID PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; ISOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMAN; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; SEQUENCE ANALYSIS; ADENOVIRUS; ALLELE; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; GENETICS; METABOLISM; MOUSE MUTANT;

ADENOVIRIDAE; ALLELES; ANIMALS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CELLS, CULTURED; CHOLESTEROL, VLDL; HEPATOCYTES; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN ISOFORMS; RECEPTORS, LDL;

EID: 44849085120     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.164863     Document Type: Article

References (40)

1. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
2. Mahley RW, Rail SC Jr. Apolipoprotein E. far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
3. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for pro-teoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007;117:94-98.
4. Shimano H, Namba Y, Ohsuga J, Kawamura M, Yamamoto K, Shimada M, Gotoda T, Harada K, Yazaki Y, Yamada N. Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice. J Clin Invest, 1994;93:2215-2223.
5. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257:2518-2521.
6. Bohnet K, Pillot T, Visvikis S, Sabolovic N, Siest G. Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J Lipid Res. 1996;37:1316-1324.
7. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103: 1579-1586.
8. Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, Mahley RW. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and mem-branes from liver and adrenal of rats, rabbits, and cows. J Clin Invest. 1981:68:1075-1085.
9. Mamotte CD, Sturm M, Foo JI, van Bockxmeer FM, Taylor RR. Com-parison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes. Am J Physiol. 1999;276:E553-E557.
10. Gylling H, Kontula K, Miettinen TA. Cholesterol absorption and metab-olism and LDL kinetics in healthy men with different apoprotein E phenotypes and apoprotein B Xba I and LDL receptor Pvu II genotypes. Arterioscler Thromb Vasc Biol. 1995;15:208-213.
11. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol. 2000;11:243-251.
12. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
13. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest. 1986;78:815-821.
14. Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 1988;42:104-112.
15. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. Targeted, replacement of the mouse apoli-poprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272:17972-17980.
16. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipo-proteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 1998; 102:130-135.
17. Knouff C, Malloy S, Wilder J, Altenburg MK, Maeda N. Doubling expression of the low density lipoprotein receptor by truncation of the 3'-untranslated region sequence ameliorates type III hyperlipoprotein-emia in mice expressing the human apoe2 isoform. J Biol Chem. 2001; 276:3856-3862.
18. Malloy SI, Altenburg MK, Knouff C, Lanningham-Foster L, Parks JS, Maeda N. Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3. Arterioscler Thromb Vasc Biol. 2004; 24:91-97.
19. Altenburg MK, Johnson LA, Wilder JC, Maeda N. Apolipoprotein E4 in macrophages enhances atherogenesis in an LDL receptor dependent manner. J Biol Chem. 2007.
20. Lucic D, Huang ZH, Gu de S, Altenburg MK, Maeda N, Mazzone T. Regulation of macrophage apoE secretion and sterol efflux by the LDL receptor. J Lipid Res. 2007;48:366-372.
21. van Dijk KW, van Vlijmen BJ, de Winther MP, van 't Hof B, van der Zee A, van der Boom H, Havekes LM, Hofker MH. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression. Arterioscler Thromb Vasc Biol. 1999:19:2945-2951.
22. Farkas MH, Swift LL, Hasty AH, Linton MF, Fazio S. The recycling of apolipoprotein E in primary cultures of mouse hepatocytes. Evidence for a physiologic connection to high density lipoprotein metabolism. J Biol Chem. 2003;278:9412-9417.
23. Dekroon RM, Armati PJ. Endocytosis of apoE-EGFP by primary human brain cultures. Cell Biol Int. 2002;26:761-770.
24. Stephan ZF, Yurachek EC. Rapid fluorometric assay of LDL receptor activity by Dil-labeled LDL. J Lipid Res. 1993;34:325-330.
25. Lorenz JN, Gruenstein E. A simple, nonradioactive method for evaluating single-nephron filtration rate using FITC-inulin. Am J Physiol. 1999:276: F172-F177.
26. Kawakami H., Hirano H. Lectin-binding patterns on the plasma mem-branes of dissociated rat liver cells. Histochemistry. 1984;80:415-420.
27. Gregg RE, Zech LA, Brewer HB Jr. Apolipoprotein E alleles in severe hypertriglyceridaemia. Lancet. 1983;1:353.
28. Hamilton RL, Wong JS, Guo LS, Krisans S, Havel RJ. Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res. 1990;31:1589-1603.
29. Linton MF, Hasty AH, Babaev VR, Fazio S. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest. 1998;101:1726-1736.
30. Raffai RL, Hasty AH, Wang Y, Mettler SE, Sanan DA, Linton MF, Fazio S, Weisgraber KH. Hepatocyte-derived ApoE is more effective than non-hepatocyte-derived ApoE in remnant lipoprotein clearance. J Biol Chem. 2003:278:11670-11675.
31. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997; 38:2173-2192.
32. Yu KC, Jiang Y, Chen W, Cooper AD. Rapid initial removal of chylo-micron remnants by the mouse liver does not require hepatically localized apolipoprotein E. J Lipid Res. 2000;41:1715-1727.
33. Heeren J, Grewal T, Jackle S, Beisiegel U. Recycling of apolipoprotein E and lipoprotein lipase through endosomal compartments in vivo. J Biol Chem. 2001:276:42333-42338.
34. Heeren J, Grewal T, Laatsch A, Becker N, Rinninger F, Rye KA, Beisiegel U. Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J Biol Chem. 2004;279: 55483-55492.
35. Swift LL, Farkas MH, Major AS, Valyi-Nagy K, Linton MF, Fazio S. A recycling pathway for resecretion of internalized apolipoprotein E in liver cells. J Biol Chem. 2001;276:22965-22970.
36. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA. 1993;90:2812-2816.
37. Yokode M, Hammer RE, Ishibashi S, Brown MS, Goldstein JL. Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors. Science. 1990:250:1273-1275.
38. Jones C, Garuti R, Michaely P, Li. WP, Maeda N, Cohen JC, Herz J, Hobbs HH. Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J Clin Invest. 2007;117:165-174.
39. Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem. 1994;269:13421-13428.
40. Huang Y, Liu XQ, Rail SC Jr, Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem. 1998;273:17483-17490.